trial · primary record
Rapcabtagene autoleucel (YTB323)
Large-cell Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2028-08 |
| Primary endpoint | Minimal Residual Disease (MRD) Conversion Rate at Day 90 |
| Registry ID | NCT07443137 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:56.041Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07443137
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.